Vernakalant bests amiodarone for the conversion of acute AF

From, 17 May 2010 (Heart Rhythm Society Annual Conference, Denver)

Denver, CO – The use of vernakalant (Merck/Cardiome Pharma) is more effective than amiodarone for the rapid conversion of atrial fibrillation (AF) to sinus rhythm and is associated with a higher rate of symptom relief, according to the results of a new study [1]. Vernakalant was shown to be safe and well tolerated and was also associated with greater improvements in quality of life.
The results of the study, known as the AVRO trial, were presented by Dr A John Camm (St George’s University, London, UK) during the late-breaking clinical-trials session here at the Heart Rhythm Society 2010 Scientific Sessions. Continue reading